BioCentury | Mar 18, 2021

Led by ex-Springworks exec, Pyxis forges deal to gain access to Pfizer’s ADCs, platform tech

Pyxis CEO Lara Sullivan has struck a deal with her former employer, Pfizer, that adds two preclinical therapies to the biotech’s pipeline as well as a license to the pharma’s ADC platform to develop more programs....
BioCentury | Jan 23, 2019
Distillery Therapeutics


INDICATION: Depression Mouse studies suggest agonizing CB1 could help treat depression. In a mouse model of depression, optogenetic activation of synaptic circuits involving cholecystokinin (CCK)-positive neurons in the basal lateral amygdala and dopamine D2 receptor...
BioCentury | Jun 5, 2018
Distillery Techniques

Drug delivery

TECHNOLOGY: Targeting domains; other Circular single-stranded DNA (CSSD)-based PTK7-targeting aptamers could be used to deliver cancer therapies. The aptamers consist of CSSD engineered to target PTK7 -- a protein expressed on many cancers -- and...
BioCentury | Oct 5, 2017
Translation in Brief

SSRIs' first responders

Researchers at The Rockefeller University have identified a role for CCK-expressing neurons in initiating responses to SSRIs for depression and manipulated the neurons to recapitulate the drugs' effects. The findings could lead to faster-acting antidepressants...
BioCentury | Jul 13, 2017
Translation in Brief

Mind over matter

In the latest link between the GI tract and the CNS, a team from the Max Delbrück Center for Molecular Medicine has identified the synaptic organizers CADM1 and CADM2 as targets in the gut-brain axis...
BioCentury | Jan 25, 2017
Distillery Techniques

Drug delivery

TECHNOLOGY: Targeting domains A DNA-based “lock-and-key” system that targets pairs of receptors could be used for cell type-specific delivery of therapeutic siRNAs. The system consisted of a hairpin DNA “key” and two receptor-specific aptamer “locks,”...
BioCentury | Nov 4, 2016
Clinical News

PF-06647020: Ph I data

Data from 22 evaluable patients with recurrent ovarian cancer in the dose-expansion portion of an open-label, U.S. and Spanish Phase I trial showed that the recommended Phase II dose of 2.8 mg/kg IV PF-06647020 every...
BioCentury | Jun 13, 2016
Product Development

Small cell synergy

Investors and others watching data coming from the American Society of Clinical Oncology meeting were quick to pan overall survival data from a Phase I study of single-agent Rova-T rovalpituzumab tesirine in recurrent small cell...
BioCentury | Apr 24, 2014
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Non-small cell lung cancer (NSCLC) PTK7 protein tyrosine kinase 7 (PTK7; CCK4) Studies in mice and patient samples suggest inhibiting PTK7 could be useful for...
BioCentury | Jun 28, 2012

Pharma compounds at the crossroads

The National Center for Advancing Translational Sciences (NCATS) has disclosed details about the first library of therapeutics in its Discovering New Therapeutic Uses for Existing Molecules program ( see "Repurposing pharma compounds"). The compounds provided by...
Items per page:
1 - 10 of 47